TD Cowen Maintains Buy on AbbVie, Raises Price Target to $225
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steve Scala has maintained a Buy rating on AbbVie and raised the price target from $195 to $225, indicating confidence in the company's future performance.
October 07, 2024 | 5:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen has increased its price target for AbbVie from $195 to $225, maintaining a Buy rating. This suggests a positive outlook for AbbVie's stock performance.
The increase in price target from $195 to $225 by TD Cowen, along with the maintained Buy rating, indicates strong confidence in AbbVie's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in AbbVie's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100